Comparison
Retatrutide vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2381089-83-2
2179963-22-7
Molecular weight
4731.6 g/mol
4727 g/mol
Half-life
144 h
168 h
Sequence
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
4
2
Effects recorded
4
3
Open conflicts
0
0
Documented adverse events
2
2